Guardant Health (NASDAQ:GH):
Q4 GAAP EPS of -$0.30 beats by $0.05.
Revenue of $32.87M (+64.3% Y/Y) beats by $6.99M.
https://seekingalpha.com/news/3442056-guardant-health-beats-…
Obviously this is a company that is about what’s too come (FDA approval, reimbursement approvals,widespread adoption of it biomarker assay for numerous cancers, prophylactic pre screening, post disease ID follow-up, etc…) , more than what’s recently happened, but at this point things look pretty good and the future is quite bright…
https://www.fool.com/investing/2019/03/12/why-guardant-healt…